Cite
Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
MLA
Lotan, Yair, et al. “Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after Bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.” The Journal of Urology, vol. 202, no. 5, Nov. 2019, pp. 920–26. EBSCOhost, https://doi.org/10.1097/JU.0000000000000355.
APA
Lotan, Y., Inman, B. A., Davis, L. G., Kassouf, W., Messing, E., Daneshmand, S., Canter, D., Marble, H. T., Joseph, A. M., Jewell, S., & Boorjian, S. A. (2019). Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. The Journal of Urology, 202(5), 920–926. https://doi.org/10.1097/JU.0000000000000355
Chicago
Lotan, Yair, Brant A Inman, Leah Gerber Davis, Wassim Kassouf, Edward Messing, Siamak Daneshmand, Daniel Canter, et al. 2019. “Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after Bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.” The Journal of Urology 202 (5): 920–26. doi:10.1097/JU.0000000000000355.